晚期非小细胞肺癌抗PD-1治疗中的影像学假性进展
该回顾性研究分析了3年内接受抗PD-1治疗的228例晚期NSCLC患者,其中166例可评估,80%接受纳武利尤单抗。iRRC和iRECIST较RECIST 1.1更准确地将假性进展归类为非进展。
要点
- 晚期NSCLC抗PD-1治疗中影像学假性进展发生率为2%。
- 临床怀疑假性进展者占9%,但仅少数经复查证实。
- iRRC和iRECIST比RECIST 1.1更准确识别假性进展。
核心结论
- 影像学假性进展在接受抗PD-1治疗的NSCLC患者中不常见,但临床处理具有挑战性。
研究设计与样本
- 回顾性分析3年内在本机构接受抗PD-1治疗的228例连续NSCLC患者,166例可评估。
主要发现
- 166例可评估患者中80%接受纳武利尤单抗。
- 3例(2%)在首次复查影像时证实影像学假性进展。
- iRRC和iRECIST均未将3例假性进展判为进展,而RECIST 1.1均判为进展。
关键数值与推荐
- 影像学假性进展发生率2%(3/166)。
临床怎么用
- 对治疗早期出现肿瘤增大或新病灶者应警惕假性进展可能,避免过早停药。
- 评估疗效时可结合iRRC或iRECIST以更准确识别假性进展。
局限性
- 回顾性单中心研究,样本量有限。
- 部分患者因缺乏随访影像或临床数据被排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anti-programmed cell death protein 1 (PD-1) therapy can lead to unconventional tumor responses, including radiologic pseudoprogression. Here we have determined the real-world incidence of radiologic pseudoprogression in advanced NSCLC and compared radiologic response criteria for assessment of disease response. METHODS: The electronic medical records of all patients with NSCLC who were receiving anti-PD-1 therapy at our institution over a 3-year period were retrospectively reviewed, and patients with clinically suspected radiologic pseudoprogression were identified. Patients without available follow-up imaging or clinical data were excluded. Imaging examinations were then analyzed to determine whether progression was confirmed on subsequent reimaging. Assessments of tumor response by the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (RECIST 1.1), the unidimensional immune-related response criteria (iRRC), and the iRECIST criteria for all patients were performed and compared. RESULTS: A total of 228 consecutive patients began receiving anti-PD-1 therapy over a 3-year period. Of the 166 of these patients who were evaluable, most (80%) received nivolumab. Fifteen patients (9%) were clinically suspected of having radiologic pseudoprogression on account of tumor enlargement and/or development of new lesions on computed tomography images during the first 4 to 6 weeks of therapy, and they continued receiving anti-PD-1 therapy. Three of these patients (2%) demonstrated evidence of radiologic pseudoprogression at first reimaging. The iRRC and immune RECIST criteria were more accurate in classifying radiologic pseudoprogression as nonprogression; none of the three cases were deemed progression by the iRRC or immune RECIST, whereas all three cases were determined to be progression according to the Response Evaluation Criteria in Solid Tumors, version 1.1. CONCLUSIONS: Radiologic pseudoprogression is a clinical challenge but an uncommon occurrence in patients with NSCLC who are receiving anti-PD-1 therapy.
引用
- Katz SI, Hammer M, Bagley SJ, et al. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29738824. doi:10.1016/j.jtho.2018.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。